Beginning in the mid-1980s, an epidemic of severe invasive infections caused by Streptococcus pyogenes (S. pyogenes), also known as group A streptococcus (GAS), occurred in the United States, Europe, and elsewhere. The general public became much more aware of these serious and sometimes fatal infections, commonly known as the “flesh-eating disease.” Potent cytotoxins produced by this human pathogen contribute to the infection. A new study in The American Journal of Pathology reports that the bacteria’s full virulence is dependent on the presence of two specific cytotoxins, NADase (SPN) and streptolysin O (SLO).
Scanning electron micrograph of the interaction of Streptococcus pyogenes (rounded blue objects) with a human neutrophil (large purple objects with ruffles and extensions).
Beginning in the mid-1980s, an epidemic of severe invasive infections caused by Streptococcus pyogenes (S. pyogenes), also known as group A streptococcus (GAS), occurred in the United States, Europe, and elsewhere. The general public became much more aware of these serious and sometimes fatal infections, commonly known as the “flesh-eating disease.” Potent cytotoxins produced by this human pathogen contribute to the infection. A new study in The American Journal of Pathology reports that the bacteria’s full virulence is dependent on the presence of two specific cytotoxins, NADase (SPN) and streptolysin O (SLO).
Bacteria produce cytotoxins that can cause cell death and result in infections of the deep fascia and other tissues, including necrotizing fasciitis. “Our research revealed that the most severe form of the disease requires two cytotoxins. If either one or both are missing, the infection is much less dangerous,” explained lead investigator James M. Musser, MD, PhD, chairman of the Department of Pathology and Genomic Medicine at Houston Methodist Research Institute (Houston, TX).
To evaluate how the toxins SPN and SLO act together, investigators used mice infected with genetically altered S. pyogenes strains that produced either, both, or neither of the toxins. They found that mutant strains lacking either SPN or SLO or both do not cause the most severe forms of necrotizing fasciitis, necrotizing myositis, bacteremia, and other soft tissue infections. Production of both toxins was required for full infection virulence.
Resistance to bacterial infections depends in part on innate immunity conferred by white blood cells, including polymorphonuclear leukocytes (primarily neutrophils). The researchers found evidence that infections with SPN- and SLO-deficient S. pyogenes could be controlled better because they were less likely to resist the bactericidal effects of human polymorphonuclear leukocytes.
According to the Centers for Disease Control and Prevention, approximately 700 to 1,100 cases of necrotizing fasciitis caused by group A streptococcus have occurred yearly since 2010. Although the disease primarily affects the young and old and those with underlying chronic conditions, it may also develop in healthy individuals. Transmission occurs person-to-person, many times through a break in the skin.
“We do not have a Group A strep vaccine that works right now,” commented Dr. Musser. “The information we gained from this research may help to develop more effective therapeutics, such as inhibitors of these two toxins, or even a vaccine.”
The article is “Contribution of Secreted NADase and Streptolysin O to the Pathogenesis of Epidemic Serotype M1 Streptococcus pyogenes Infections,” by Luchang Zhu, Randall J. Olsen, Jessica D. Lee, Adeline R. Porter, Frank R. DeLeo, and James M. Musser (http://dx.doi.org/10.1016/j.ajpath.2016.11.003). It will be published in The American Journal of Pathology, volume 187, issue 3 (March 2017) by Elsevier.
This research was supported by funds from the Fondren Foundation, and in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Jessica D. Lee was supported by the Rice University Century Scholar program.
Source: Houston Methodist
Together We Rise: Why AORN Expo 2025 Is a Must for Every Perioperative Nurse
March 31st 2025From April 5 to 8, 2025, thousands of perioperative nurses will gather in Boston for the 2025 AORN Global Surgical Conference & Expo—a transformational experience designed to elevate nursing practice, build lifelong connections, and advance surgical care.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.
Invisible, Indispensable: The Vital Role of AHRQ in Infection Prevention
March 25th 2025With health care systems under strain and infection preventionists being laid off nationwide, a little-known federal agency stands as a last line of defense against preventable patient harm. Yet the Agency for Healthcare Research and Quality (AHRQ) is now facing devastating cuts—threatening decades of progress in patient safety.